Business Context and Reporting Period
Lisata Therapeutics, Inc. (LSTA) is a clinical-stage pharmaceutical company focused on developing certepetide, an investigational drug designed to enhance the delivery of anti-cancer therapies to solid tumors via the CendR active transport pathway. The company operates as a single segment and is currently conducting Phase 2 clinical trials for metastatic pancreatic ductal adenocarcinoma (mPDAC) and other solid tumors. This Form 10-K covers the fiscal year ended December 31, 2024.
Key Financial Metrics
| Metric (in thousands) | 2024 | 2023 |
|---|---|---|
| Revenue | $1,000 | $0 |
| Net Loss | $(19,985) | $(20,840) |
| Operating Expenses | $23,409 | $25,708 |
| Cash and Cash Equivalents | $16,209 | $22,593 |
| Marketable Securities | $15,036 | $27,942 |
| Total Liquidity (Cash + Securities) | $31,245 | $50,535 |
| Net Cash Used in Operating Activities | $(19,356) | $(20,032) |
| Working Capital | $28,965 | $47,334 |
Note: Revenue in 2024 consisted of a $1.0 million upfront license fee from Kuva Labs, Inc. The company has no debt obligations listed on the balance sheet.
Material Changes vs. Prior Period
- Revenue Generation: The company recorded $1.0 million in revenue in 2024, compared to zero in 2023, driven by a new exclusive license agreement.
- Expense Reduction: Total operating expenses decreased by $2.3 million (8.9%) to $23.4 million. Research and Development (R&D) expenses fell by $1.4 million, primarily due to reduced spend on the ASCEND trial (which completed enrollment) and lower chemistry, manufacturing, and controls (CMC) costs. General and Administrative (G&A) expenses decreased by $0.9 million, aided by the absence of one-time severance costs incurred in 2023.
- Liquidity Decline: Total cash and marketable securities decreased by approximately $19.3 million year-over-year, reflecting continued operating losses and lower investment income.
- Tax Benefits: The company recognized a $0.8 million income tax benefit in 2024 from the sale of New Jersey Net Operating Losses (NOLs), compared to a $2.3 million benefit in 2023.
Outlook, Risks, and Management Commentary
- Clinical Progress: Preliminary data from the ASCEND trial (Cohort A) reported in January 2025 showed a median overall survival of 12.68 months for the certepetide group versus 9.72 months for placebo. No significant improvement in median progression-free survival was observed, but the safety profile remained benign.
- Liquidity Outlook: Management believes current cash and marketable securities ($31.2 million) will fund operations into early 2026. The company anticipates needing substantial additional financing to support Phase 3 trials and commercialization.
- Capital Raising: The company maintains an "At-The-Market" (ATM) offering agreement but is subject to the "Baby Shelf Limitation" due to a public float below $75 million, restricting sales to one-third of the public float in a trailing 12-month period.
- Risks: Key risks include the failure of clinical trials to demonstrate efficacy, inability to secure additional capital, dependence on third-party manufacturers, and potential delisting from Nasdaq if the stock price falls below $1.00 for 30 consecutive days.
Investor Verification Checklist
- Cash Runway: Verify the specific timeline for funding depletion and the company's concrete plans for raising capital beyond early 2026.
- ASCEND Trial Data: Review the full statistical analysis of the ASCEND trial Cohort A and the expected timeline for Cohort B data release.
- Nasdaq Compliance: Monitor the stock price relative to the $1.00 minimum bid price requirement to assess delisting risk.
- License Agreements: Review the terms of the Kuva Labs agreement and the Qilu Pharmaceuticals agreement, specifically regarding milestone payments and royalty structures.
- Settlement Obligations: Confirm the status of the $0.5 million settlement payment to Lingmed Limited and any future contingent payments.